Skip to main content
Article thumbnail
Location of Repository

Almotriptan in the treatment of migraine

By Giorgio Sandrini, Armando Perrotta, Natalia L Arce Leal, Simona Buscone and Giuseppe Nappi


Almotriptan is an orally administered, highly selective serotonin 5-HT(1B/1D) receptor agonist that is effective in the acute treatment of moderate to severe migraine attacks. Since its introduction on to the market in 2001, several studies involving a large number of migraine patients have confirmed its efficacy and tolerability profile. Almotriptan, was found to be among the best-responding triptans in terms of pain relief and pain-free rate at 2 h. It has been reported that almotriptan has the best sustained pain-free (SPF) rate and the lowest adverse events (AEs) rate of all the triptans. When these clinical characteristics were combined to form the composite endpoint SPF and no AEs (SNAE), almotriptan emerged as the triptan with the best efficacy and tolerability profile. It also showed a good efficacy profile during the early treatment (within 1 h of onset) of migraine attacks characterized by moderate pain intensity. On the basis of these findings, almotriptan may be considered a therapeutic option for the acute treatment of migraine attacks

Topics: Expert Opinion
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (1996). 5-carboxamido- tryptamine CP-122,288 and dihydroergotamine but not sumatriptan CP-93,129 and serotonin-5-O-carboxymethyl-glycyl-tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors. Mol Pharmacol,
    2. (2003). A review of the clinical effi cacy and tolerability of almotriptan in acute migraine. Expert Opin Pharmacother,
    3. (2003). A review of the effects of almotriptan and other triptans on clinical trial outcomes that are meaningful to patients with migraine. Clin Ther,
    4. (2002). Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers.
    5. (2007). Almotriptan and zolmitriptan in the acute treatment of migraine.
    6. (2004). Almotriptan improves response rates when treatment is within 1 hour of migraine onset.
    7. (2006). Almotriptan in the acute treatment of migraine in patients 11-17 years old: an open-label pilot study of effi cacy and safety.
    8. (2002). Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials.
    9. (2002). Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial.
    10. (2002). Almotriptan, a new anti-migraine agent: a review. CNS Drug Rev,
    11. (1990). Basic mechanisms in vascular headache.
    12. (1999). Burden of migraine in the United States: disability and economic costs.
    13. (2004). Clinical benefi ts of early triptan therapy for migraine. Cephalalgia, 24(Suppl 2):24–30.
    14. (2005). Clinical pharmacokinetics of almotriptan, a serotonin 5-HT1B/1D receptor agonist for the treatment of migraine.
    15. (2000). Consistent effi cacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study.
    16. (2005). Cost of disorders of the brain in Europe.
    17. (2002). Determinants of migrainespecifi c quality of life.
    18. (2003). Early intervention with almotriptan improves sustained pain-free response in acute migraine.
    19. (2007). Early intervention with almotriptan: results of the AEGIS trial (AXERT((R)) early migraine intervention study).
    20. (2006). Effect of food intake on the bioavailability of almotriptan, an antimigraine compound, in healthy volunteers: an open, randomized, crossover, single-dose clinical trial.
    21. (2001). Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.
    22. (2006). Effi cacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol Sci, 27(Suppl 2):S193–7.
    23. (2006). Effi cacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebocontrolled clinical trials.
    24. (2001). Evaluation of the potential pharmacokinetic interaction between almotriptan and fl uoxetine in healthy volunteers.
    25. (2005). Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine.
    26. (2000). Functional profi le of almotriptan in animal models predictive of antimigraine activity.
    27. (2002). Global burden of disease 2000: version 2, methods and results. World Health Organization. URL:
    28. (2004). Headache Classifi cation Subcommittee of the International Headache Society.
    29. (2001). Hemodynamic and electrocardiographic effects of almotriptan in healthy volunteers.
    30. (2003). Interaction between ketoconazole and almotriptan in healthy volunteers.
    31. (2000). International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition.
    32. (2004). Is migraine a progressive brain disease?
    33. (2001). Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers.
    34. (1997). Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibitstrigeminal cell fi ring in the cat.
    35. (2006). Migraine in children and adolescents: a guide to drug treatment.
    36. (2003). Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment.
    37. (2005). Migraine: epidemiology, impact, and risk factors for progression.
    38. (1987). Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain.
    39. (2001). Oral almotriptan in the treatment of migraine: safety and tolerability.
    40. (2002). Oral Almotriptan Study Group.
    41. (2001). Oral almotriptan versus oral sumatriptan in the abortive treatment of migraine: a doubleblind, randomized, parallel-group, optimum-dose comparison.
    42. (2001). Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials.
    43. (2000). Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther,
    44. (2001). Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review.
    45. (2000). Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine.
    46. (2001). Prevalence and burden of migraine in the United States: data from the American Migraine Study II.
    47. (2002). Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized double-blind, placebo-controlled study.
    48. (1991). Stimulation of the superior sagittal sinus increases metabolic activity and blood fl ow in certain regions of the brainstem and upper cervical spinal cord of the cat.
    49. (2004). The 5-hydroxytry ptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res,
    50. (1990). The antimigraine drug sumatriptan (GR43175) selectively blocks neurogenic plasma extravasation from blood vessels in dura mater.
    51. (2006). the task
    52. (2001). Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther,
    53. (2002). Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.
    54. (2004). Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms.
    55. (2000). Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and effi cacy.
    56. (2007). Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.
    57. (2001). Vascular effects of the new antimigraine agent almotriptan on human cranial and peripheral arteries.
    58. (2002). What do patients with migraine want from acute migraine treatment? Headache, 42(Suppl 1):3–9.
    59. (2002). Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache,

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.